Acadia Pharmaceuticals Acquires Ex-North American Rights To Trofinetide And Global Rights To Neuren's NNZ-2591 In Rett Syndrome And Fragile X Syndrome; Will Make Upfront Payment Of $100M And Pay Additional Milestones To Neuren
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals has acquired the ex-North American rights to Trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X Syndrome. The deal involves an upfront payment of $100M and additional milestones to Neuren.
July 13, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acadia Pharmaceuticals has made a significant acquisition, which could potentially enhance its product portfolio and future revenue streams.
Acadia's acquisition of the rights to Trofinetide and NNZ-2591 could potentially enhance its product portfolio and open up new revenue streams. This could positively impact the company's stock in the short term as it indicates potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100